Forskolin

Catalog No.S2449 Synonyms: Coleonol

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Cited by 8 Publications

Eur J Cancer, 2014, 50(7):1310-20

PubMed: 24559688

Development, 2016, 143(12):2103-10

PubMed: 27151951

Gen Comp Endocrinol, 2016, 237:98-108

PubMed: 27570060

Reprod Domest Anim, 2018, 10.1111/rda.13304

PubMed: 30098220

Sci China Life Sci, 2018, 10.1007/s11427-018-9359-8

PubMed: 30159682

Cell Physiol Biochem, 2018, 45(3):1023-1033

PubMed: 29439250

Osteoarthritis Cartilage, 2017, 25(11):1868-1879

PubMed: 28716756

PLoS One, 2017, 12(3):e0173240

PubMed: 28253352

2 Customer Reviews

Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Targets

Adenylyl cyclase (AC) ^[1]
(A wide variety of cell types)

In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (G_s)–AC complexes. Activation of _s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of _s-Forskolin potentiation of AC activity. ^[1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HEK293	M3LCd2Z2dmO2aX;uJGF{e2G7	MXmxNEDPxE1?	NHfufmo3KGh?		MV7pcoNz\WG\|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJI93\XKneIDy[ZN{\WRiS1zIUFMh[XRiU{SzNy=>	M1W3XlI3PDN3NEm4
Mo-DCs	NFL0N45HfW6ldHnvckBCe3OjeR?=	MnPhOVAh\|ryP	NUjFNnY1OjUkgJno		MojMdJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh	NYPPS\|R6OjZ2MUK5OFg>
RBMECs	M1fEZ2Z2dmO2aX;uJGF{e2G7	M{PXRlXDqM7:TR?=	NV63O3FyOcLiaB?=		NYXi[oFv[myxY3vzJJRp\SCUYXOxJIlv[WO2aY\heIlwdiCrbnT1Z4VlKGK7IFXNRXAuUUl?	NWfIVmhiOjZ\|NUiwN\|k>
INA-6	MnHLR4VtdCCYaXHibYxqfHliQYPzZZk>	M3TMclAuOTByIN88US=>	MUO3NwKBkWh?		MWHpcoR2[2W\|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?=	MVqyOlMxPjZ{NB?=
OPM-2	MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MlT4NE0yODBizszN	Mme3O\|LjiImq		MoTabY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm=	NILXVZMzPjNyNk[yOC=>
U266	NWf5S2xmS2WubDDWbYFjcWyrdImgRZN{[Xl?	NH;KfoMxNTFyMDFOwG0>	NIrwSoY4OuLCiXi=		M4P5UIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5	M3X0e\|I3OzB4NkK0
H929	MmLsR4VtdCCYaXHibYxqfHliQYPzZZk>	MXGwMVExOCEQvF2=	NFL6ZlM4OuLCiXi=		M1zvSYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5	MUGyOlMxPjZ{NB?=
RPMI 8226	MkHZR4VtdCCYaXHibYxqfHliQYPzZZk>	NFHTXoYxNTFyMDFOwG0>	NVXVV4lYPzMkgJno		NHjJT\|NqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MYSyOlMxPjZ{NB?=
MDCK	MmHpSpVv[3Srb36gRZN{[Xl?	NIq3XmgyOCEEtV2=	MormNlQhcA>?	NYLaRpNkTE2VTx?=	NEezNoF2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB?	NED4TWszPjJyMkO1Ni=>
MDCK	NU\H[44{TnWwY4Tpc44hSXO\|YYm=	NE[2NlQyOCEEtV2=	MoXTNlQhcA>?	MlPhSG1UVw>?	MVvpcohq[mm2czD0bIUhcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gSm4h[2G3c3XkJIJ6KFSJRj5OtlE>	NYnLc4JxOjZ{MEKzOVI>
Spinal cords	NVXqZnZ3TnWwY4Tpc44hSXO\|YYm=	Mk\NNeKh\|ryP	NFfXflI{OCCvaX6=		NWLNV3p7e3SrbYXsZZRmeyClQV3QJIxmfmWucx?=	MW[yOlEzPjl{Nh?=
BeWo	NILEfVlHfW6ldHnvckBCe3OjeR?=	NEKybWUzPeLCid88US=>	NYPUTJhjOjRxNEivO\|IhcA>?		M{XGeoxm[WS\|IITvJIFvKGmwY4LlZZNmKGmwIITo[UBmgHC{ZYPzbY9vKG:oIH;0bIVzKG[3c3nvckBu[XKtZYLz	NFXne4kzPjB3M{W0PS=>
bovine oocytes	Mof1SpVv[3Srb36gRZN{[Xl?	NHnaV4gyODEEoN88US=>	MVGxNuKhcA>?		MlLsbY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCQUGDBJIFv\C:xcjDOVHBEKHSxIIP0bY12dGG2ZTDy[ZN2dXC2aX;uJI9nKG2naX;zbZM>	NX3nW292OjZyNUG2NVE>
Caco-2	MUnGeY5kfGmxbjDBd5NigQ>?	M{nSWFAvOS9zL{GwJO69VQ>?	M1TTbVIxyqCvaX6=		NV7UUFh1cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ2FOWCCuZY\lcJM>	NF;UTm4zPjB2OUGwNi=>
Caco-2	M{e3[GZ2dmO2aX;uJGF{e2G7	M3naflAvOS9zL{GwJO69VQ>?	MWmyOEBp		MkPmbY5kemWjc3XzJG1TWDJicILveIVqdiCuZY\lcC=>	NYPN[JNXOjZyNEmxNFI>
AML-12	NYnjboozTnWwY4Tpc44hSXO\|YYm=	Moe3NlAh\|ryP	NV3weHJNOyCq		NVn0S5JRfXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=>	NF6x[\|QzPjB2OEm4OS=>
AML-12	MW\GeY5kfGmxbjDBd5NigQ>?	MlHSNlAh\|ryP	NVHTSlNZOS16IHi=		NWLqd4pYcW6lcnXhd4V{KGeudXPvd4UheHKxZIXjeIlwdg>?	NWKwbXZKOjZyNEi5PFU>
AML-12	NV3QemlPTnWwY4Tpc44hSXO\|YYm=	MW[yNEDPxE1?	Ml7GN{Bp		MXX1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN?	NHfFbYwzPjB2OEm4OS=>
AML-12	M3TZbGZ2dmO2aX;uJGF{e2G7	MUGyNEDPxE1?	MX2zJIg>		NIHKToFqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCxZjDDVnREOsLi	NVvId25SOjZyNEi5PFU>
RBMECs	NHnXUllHfW6ldHnvckBCe3OjeR?=	NUjvSVZ7PcLizszN	NFjnU3cyKGh?		M2TTOIlvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh	NHzMbnkzPjB2NE[2Ny=>
EndoC-βH1	MYLGeY5kfGmxbjDBd5NigQ>?	NHvp[ng2yqEQvF2=	M3\wV\|EhcA>?		MmTIdI91\W62aXH0[ZMh\2y3Y3;z[U1qdmS3Y3XkJIlve3WuaX6gd4VkemW2aX;uJIlvKHSqZTDwdoV{\W6lZTDv[kBodHWlb4Pl	NVr1[Y06OjZyMki1OlI>
EndoC-βH1	M2XoXGZ2dmO2aX;uJGF{e2G7	NGrG[nY2yqEQvF2=	NXqxOZlQOSCq		MoDYcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>?	NEDuXGIzPjB{OEW2Ni=>
SH-SY5Y	NFvzWpdHfW6ldHnvckBCe3OjeR?=	NUXPR\|Y1OzBizszN	NHjqN40{OCCvaX6=	NFzKR4pFVVOR	NIS4RZR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUh[WO2aY\heIlwdiCxZjDQT2E>	MVGyOlAzPTF\|Nx?=
PC-3	MX3GeY5kfGmxbjDBd5NigQ>?	NWHKNW94PDBiwsXN	MnnmNkBp	M2H1OGROW09?	MmHvcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w	NWr6eFJ6OjZyMkO4N\|Y>
PC-3	NVXSVWwzS2WubDDWbYFjcWyrdImgRZN{[Xl?	M1zoZ\|QxKML3TR?=	MnPUNlQwPDhxN{KgbC=>	M{jFV2ROW09?	NXTYOYl7\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm=	NFzyV2szPjB{M{izOi=>
SCG	NV3rclVXTnWwY4Tpc44hSXO\|YYm=	MmPMNlAh\|ryPwrC=		NFXSOnJFVVOR	NYLMUmNZemW4ZYLzbYJtgSC\|dYDwdoV{e2W\|IFnLWkB4cXSqIHGgTWM2OCCxZjCyOE41KM7:TR?=	Mke3NlU6PjJzM{K=
HEK-293	NEPaPIhHfW6ldHnvckBCe3OjeR?=	NH;Eco0{PSEQvF5CpC=>		NFnhW4JFVVOR	M1vVNIlv\HWlZYOgZUBkd26\|cHnjeY92eyEkgKzpcoFkfGm4YYTpc47jiJ1ib3[geIhmKEu4Mj6xJIN2enKnboS=	MoKyNlU6PjJzM{K=
SCG	NUP3codlTnWwY4Tpc44hSXO\|YYm=	MY[xNFAh\|ryPwrC=		MkLISG1UVw>?	MVXy[YR2[2W\|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM>	NXTveldsOjV7NkKxN\|I>
PCCL3	M3XPNWZ2dmO2aX;uJGF{e2G7	NV7sWZB2OTBiwsXN	M{S1VVI1KGh?		MVnlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt?	MYWyOVk3ODl3Nh?=
3T3-L1 preadipocytes	NYHJXFRJTnWwY4Tpc44hSXO\|YYm=	NYXMRllWOTBizszNxsA>	NFjlWVEyOiCq		NEeyWZNqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36=	MWSyOVkzQDB3OB?=
H295R	MXvGeY5kfGmxbjDBd5NigQ>?	MV2xNOKh\|ryP	MVK0POKhcA>?		NI\EUmhqdmO{ZXHz[ZMhe3Sncn;p[EBu\XSjYn;sbZRmeyCrbjD0bIUh[W6mcn;n[Y4tKG2rbnXyZYxwNSCjbnSg[4x2[2:lb4L0bYNwcWRicHH0bJdigXN?	MYmyOVg3QTV3Nh?=
PBMC	Ml7jSpVv[3Srb36gRZN{[Xl?	M{O2b\|UxyqEQvF2=	MmfTNlTDqGkEoB?=		NHH1dWFqdmirYnn0d{B1cGViaX7jdoVie2WmIIPlZ5JmfGmxbjDv[kBVVkZiaX7keYNm\CCkeTD0bIUhTFCH	NXrGZpdoOjV6Nk[wO\|k>
GLUTag	NUPCbJYxTnWwY4Tpc44hSXO\|YYm=	NEexeVcyOOLCidM1US=>	M3TDd\|AwOi92IHi=		NIK3c\|J{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z	MYCyOVg{OjZ\|MR?=
GLUTag	M4H6e2Z2dmO2aX;uJGF{e2G7	M1rDbVEx6oDLwsXN	NVr3cm5VPCCq		NV3iRXRncW6lcnXhd4V{KHSqZTDwR3JGSiCuZY\lcJMhf2m2aDD0bIUhUUKPWB?=	NETt[mczPTh\|Mk[zNS=>
BAECs	MV\GeY5kfGmxbjDBd5NigQ>?	NFS5[FIzPSEQvF2=	NVHBZldPOjRiaB?=		NWfmd3Rz\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=>	NH31VY8zPTd7OEiyOi=>
PC12	MmCwSpVv[3Srb36gRZN{[Xl?	NFfFO3EzPcLizszN	M{HrVFQ5KGh?		M3H4e4FkfGm4YYTld{BkSU2S	MUKyOVc3QTNyNR?=
GH3	M1XtdmZ2dmO2aX;uJGF{e2G7	NHXoZWYyyqEQvF2=	MYK2MYg>		NEDsc2ZifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?=	M1rGbFI2PzJ5MEG4
GH3	NYCxPHhPTnWwY4Tpc44hSXO\|YYm=	NIO0cZkyyqEQvF2=	MXS2MYg>		MWjpcoR2[2W\|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?=	M2PORlI2PzJ5MEG4
BeWo	MlqySpVv[3Srb36gRZN{[Xl?	NEX5RlkyOOLCit88UeKh	NHXHNoM4OiCq	M4jNNWROW09?	NHzXcIdu\WSrYYTld{BD\VexIHPlcIwh\GmoZnXy[Y51cWG2aX;u	M2npS\|I2PzF\|NEK1
oocytes	MXHGeY5kfGmxbjDBd5NigQ>?	NX7EPJRRPSEQvF2=	MkDmNlQhcA>?		MULheJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>?	NVPUVpZ6OjV5MEe4OVQ>
SC	M1H0[GZ2dmO2aX;uJGF{e2G7	NUKzOY9UOC53IN88US=>	MUOyOEBp		MYntbY1q[2u\|IITo[UBm\m[nY4Sgc4Yh[0GPUDDhcoFtd2e\|IH;uJG8yKGGwZDDNRnAh\XiycnXzd4lwdg>?	MojuNlU4ODV6N{S=
SC	NXHCdldGTnWwY4Tpc44hSXO\|YYm=	M1XHT\|AvPSEQvF2=	NILJNFc4OiCq		NXLmclJWcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=>	M4XRe\|I2PzB3OEe0
UACC-647	NVzhdo1ZTnWwY4Tpc44hSXO\|YYm=			MlvvSG1UVw>?	NWnSe2tkdGWjZIOgeI8h[SC{aYPlJIlvKGODTWCgcIV3\Wy\|IDjFR\|UxyqB;wrCyNE4{QcLizszNLS=>	NHnVUHczPTdyM{CyOS=>
UACC-647	MYDGeY5kfGmxbjDBd5NigQ>?	MoXjNVDDqM7:TR?=	NY\DOVVPOTVibXnu	NWDxN\|FPTE2VTx?=	MVzpcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u	MV[yOVcxOzB{NR?=
UACC-647	MYLGeY5kfGmxbjDBd5NigQ>?	NHThWoIyOMLizszN	MVexOUBucW5?	Mn[zSG1UVw>?	NHzEV5FqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB?	Mn;qNlU4ODNyMkW=
SH-SY5Y	M2HGUWZ2dmO2aX;uJGF{e2G7	MmixNVDDqM7:TR?=	MnjONeKhcMLi		MorCbY5kemWjc3XzJGxWSyCjY4Tpeol1gQ>?	MXyyOVU6PzR\|Mx?=
SH-SY5Y	NUjac3FUTnWwY4Tpc44hSXO\|YYm=	NGXseHAyOMLizszN	MV:xxsBpyqB?		MXPpcoNz\WG\|ZYOgRWdEOSCvUl7BJIxmfmWu	NHHwU44zPTV7N{SzNy=>
hADSCs	M3exZmZ2dmO2aX;uJGF{e2G7	NGGwWGw26oDLwsXN	MkfCN\|AhdWmw		NX\RSJE6cW6lcnXhd4V{KGODTWCgcIV3\Wy\|	MWOyOVU6OTlyOB?=
HEK293	M1P0WWZ2dmO2aX;uJGF{e2G7	MWq15qCKyrWP	MWCzNEBucW5?		NEHmcG1qdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN?	NHrjPYYzPTV7MUmwPC=>
3T3-L1	MlPYSpVv[3Srb36gRZN{[Xl?	M3;kOFIvPS93IN88US=>	M1nGRlI1KGkEoB?=		MYjzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCDVFfMJJBzd3SnaX6g[ZhxemW\|c3nvckBifCCjbHyg[I9{\XNidHXzeIVl	MWSyOVU6ODV7Nx?=
OCI-Ly1	MWnGeY5kfGmxbjDBd5NigQ>?	MX20NOKh\|ryP	Mlq2NeKhcMLi	NH:5bJRFVVOR	MUDpcoR2[2W\|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?=	MXuyOVU4PjJ{MB?=
OCI-Ly18	MYXGeY5kfGmxbjDBd5NigQ>?	NV7yfWhoPDEEoN88US=>	NIntW3MyyqCqwrC=	NEX0WHJFVVOR	Mm\wbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO=	MYGyOVU4PjJ{MB?=
BeWo	NUf1W4F6TnWwY4Tpc44hSXO\|YYm=	MU[yNOKhyrWP	NH7UWJY1QMLiaB?=	M3j3emROW09?	M2LOe4lv[3KnYYPld{B1cGViZHnm[oVz\W62aXH0bY9vKG:oIFLlW48h[2WubIO=	NIjYUI8zPTV4Nke0NC=>
BeWo	Mn25SpVv[3Srb36gRZN{[Xl?	NWLVTlZmOjEEoNM1US=>	MUC0POKhcA>?	NV3se5lvTE2VTx?=	MUHpcoNz\WG\|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>?	NXq5cG81OjV3Nk[3OFA>
LNCaP	MnHFSpVv[3Srb36gRZN{[Xl?	NEHhcpIyOMLizszN	MlvJNVIhcMLi	NYLSbZRxTE2VTx?=	M1fl[4lv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=>	MnfhNlU2PDhyOUm=
ThGCs	MoPmSpVv[3Srb36gRZN{[Xl?	M1HMd\|Ex6oDMzszN	NFfabmY16oDMaB?=		M1LNWIF2\22nboTzJGhKTjGDIHzleoVteyC2aHH0JJdmemVic4TpcZVt[XSnZDDifUBEd0OuMh?=	Mn7kNlU1OzNyMke=
ThGCs	NIjtcGNHfW6ldHnvckBCe3OjeR?=	Mn;oNVDjiIsQvF2=	Mn[xOQKBkmh?		NEjkOo1qdmO{ZXHz[ZMhS2:FbEKtbY5lfWOnZDDFSG4zyqCpZX7lJIV5eHKnc4Ppc44>	NYH6eGFGOjV2M{OwNlc>
ThGCs	NHvlTlFHfW6ldHnvckBCe3OjeR?=	NXXBSoE{OTEkgJtOwG0>	NUHVPFFHOyCq		NYfVbot5cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?=	M3\udVI2PDN\|MEK3
RBMECs	NFTQcolHfW6ldHnvckBCe3OjeR?=	MlrQNE4xPS9yLkWvOUDPxE1?	NX\WbYtTOC5{NTDo		MWrpcoNz\WG\|ZYOgZ2FOWCClb37j[Y51emG2aX;u	M4\5cFI2PDF4NkWx
RBMECs	M2X1NGZ2dmO2aX;uJGF{e2G7	NELGfVI2yqEQvF2=	NF;UXoIyKGh?		M1fFdYJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ	M3v0UVI2PDF4NkWx
RBMECs	MWrGeY5kfGmxbjDBd5NigQ>?	MoPBOeKh\|ryP	NGHCT\|gyKGh?		NWTvS3IzeHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn	NYTNTZpQOjV2MU[2OVE>
RBMECs	M17NcWZ2dmO2aX;uJGF{e2G7	NYH5NlBEPcLizszN	MWSxJIg>		NGPkemFxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gTHJRKG[udYigZYNzd3O\|IITo[UBDXEJiaX7keYNm\CCkeTCgSW1CWC2LSR?=	MX6yOVQyPjZ3MR?=
RBMECs	NEnFfHZHfW6ldHnvckBCe3OjeR?=	NHKzZmo2yqEQvF2=	NX3jbotGOSCq		MUTpcohq[mm2czD0bIUh\GWlcnXhd4VlKG:oIHHtc5VvfCCxZjDaU{0yKGmwIF3Gd{BqdmS3Y3XkJIJ6KEWPQWCtTWk>	M1HYblI2PDF4NkWx
RBMECs	MUXGeY5kfGmxbjDBd5NigQ>?	MnzhOeKh\|ryP	M2fkWlEhcA>?		MV\y[ZZmenOnczD0bIUh[2ijbnfld{BqdiCcTz2xJIRqe3S{aXL1eIlwdiC\|ZXXuJJdqfGhiRV3BVE1KUSC2cnXheI1mdnR?	MYWyOVQyPjZ3MR?=
RBMECs	M3nKd2Z2dmO2aX;uJGF{e2G7	NF\WRYs2yqEQvF2=	MUOxJIg>		Ml7HZoxw[2u\|IITo[UBGVUGSLVnJMYlv\HWlZXSgZ4hidmenIHnuJG1NSyCyaH;zdIhwenmuYYTpc44>	MWmyOVQyPjZ3MR?=
RBMECs	MnzQSpVv[3Srb36gRZN{[Xl?	M3\Zc\|XDqM7:TR?=	MYKxJIg>		NWDQd\|Y4[myxY3vzJJRp\SCjY4TpckBkgXSxc3vlcIV1d25icnXhdpJidmenbXXueEB{\WWwIIfpeIghTU2DUD3JTUB1emWjdH3lcpTDqA>?	M{jvZVI2PDF4NkWx
Primary bovine chondrocytes	MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;Sb\|XPxE1?	M1vkVVQ5KGh?		M2S4UZJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz	MnOyNlU1ODZyMU[=
EM1	NFmz[mpHfW6ldHnvckBCe3OjeR?=	NFTxS4gyPeLCit88US=>	M3rVfVQ5KGh?		M3K3c5Jm\HWlZYOgeIhmKGW6cILld5Nqd25ib3dCpGxKTsLib4NCpHBVT1N{wrDpcuKhS0GOUj2gc5LDqEWSQVOyMZNqdGWwY3XkJGVOOSClZXzsd:Kh	M3y5[VI2Ozd6Nk[x
BeWo	NVK2dIF2TnWwY4Tpc44hSXO\|YYm=	NXPnVVliOjEEoNM1US=>	MlLLOFjDqGkEoB?=	NWS4eZdqTE2VT9Mg	MXTpcoNz\WG\|ZYOgeIhmKGKndHGtbGNIKHKnbHXhd4U>	NHfaPHkzPTN4MkK2NC=>
BeWo	MmThSpVv[3Srb36gRZN{[Xl?	M1viZlIxyqEEtV2=	NEn4dFM1QMLiaNMg	NUDxRnpbTE2VT9Mg	NHTGTIFld3ewcnXneYxifGW\|IITo[UBt\X[nbDDv[kBVVUWPRkG2	MU[yOVM3OjJ4MB?=
BeWo	MorSSpVv[3Srb36gRZN{[Xl?	M1jZOlIxyqEEtV2=	NX;ySHRPPDkEoHlCpC=>	NVHXRldITE2VT9Mg	NETxSGZld3ewcnXneYxifGW\|IITo[UBt\X[nbDDv[kBIS01vMR?=	NVPYZXp[OjV\|NkKyOlA>
granulosa cells	MYrGeY5kfGmxbjDBd5NigQ>?	NFTwSW4yOCEQvF2=	NXq4XIZ6OTJxMkSgbC=>		NGqzSXZqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=>	M1[y[FI2OzN7MUC1
granulosa cells	MkPzSpVv[3Srb36gRZN{[Xl?	M13qW\|ExKM7:TR?=	M1SxSFEzNzJ2IHi=		NUjwT\|NWcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp	MoXCNlU{OzlzMEW=
granulosa cells	NHrhcVBHfW6ldHnvckBCe3OjeR?=	MXWxNEDPxE1?	MVeyOEBp		M4jafolv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJGRPSS:ycn;0[YlvKGOxbYDs[Zg>	NGHkRlgzPTN\|OUGwOS=>
granulosa cells	MnW5SpVv[3Srb36gRZN{[Xl?	MUmxNEDPxE1?	MnfjNlQhcA>?		NYPye3lycW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVmdUOiCycn;tc5RmeiCjY4Tpeol1gQ>?	MVqyOVM{QTFyNR?=
SK-N-AS	M1;rUGNmdGxiVnnhZoltcXS7IFHzd4F6	M2rTdlExKM7:TdMg	M1\TXFI1NzR6IHi=		NVXVN3JM\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>?	M1vxRVI2OjZ4ME[z
SK-N-AS	MmjmSpVv[3Srb36gRZN{[Xl?	NHnnSIQyOCEQvF5CpC=>	MlPxNlQhcA>?		NH7sPYVqdmO{ZXHz[ZMhfGinIHPBUXAhdGW4ZXzzxsA>	MojJNlUzPjZyNkO=
SK-N-AS	MlOwSpVv[3Srb36gRZN{[Xl?	M3nrPFExKM7:TdMg	NVzO[XlOOjRiaB?=		NVjpTHBRcW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKGO7Y3zpckBFOQ>?	NGP0OpQzPTJ4NkC2Ny=>
SK-N-AS	MnPsSpVv[3Srb36gRZN{[Xl?	NGPOVGcyOCEQvF5CpC=>	MUGzNEBucW5?		MXfpcoR2[2W\|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw	MYGyOVI3PjB4Mx?=
SK-N-AS	NUe3ZW8xTnWwY4Tpc44hSXO\|YYm=	NELWbo4yOCEQvF5CpC=>	NHPrPXoyOC9\|MD:2NEBucW5?		NFHVdnFqdmO{ZXHz[ZMhdGW4ZXzzJI9nKHBvzsKtZ4F1\W6rbjCod4VzPjd3KTDhcoQhcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gdE3Pui2lYYTlcolvKCi\|ZYK2O\|UqKGmwIDjw[ZJqMW63Y3zlZZIhemWpaX;udy=>	MUSyOVI3PjB4Mx?=
SK-N-SH	NVLmbo9kS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mn[yNVAh\|ryPwrC=	MWS0PEBp		NXnxOnB1\W6qYX7j[ZMhW0tvTj3TTEBv\XW{b3LsZZN1d22jIHPlcIwhfmmjYnnsbZR6	NXXqR5NoOjV{Nk[wOlM>
HEK‐CFTR	M1jIPWZ2dmO2aX;uJGF{e2G7	M{W2VVLjiJN3MNMg{txO	MojONE0yOiCvaX6=	MV3EUXNQyqB?	MWrpcoR2[2W\|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB?	NETUXlczPTJ4M{KwOy=>
L6	MWXGeY5kfGmxbjDBd5NigQ>?	NUTyV2s5PDBiwsXN	MY[yOEBp		MXnpcohq[mm2czDEUWgyNWmwZIXj[YQhSWu2IHHjeIl3[XSrb36=	NVnEXHc3OjV{NEe1OVA>
MIN6	M3LmfGZ2dmO2aX;uJGF{e2G7	MYSxNEDPxE4EoB?=	M2qwfFMhcA>?		NXHueI1GcW6lcnXhd4V{KER\|IH3SUmEh\XiycnXzd4lwdg>?	M1vaZ\|I2OjRzMUK0
ventricular cardiomyocytes	M2DoeWZ2dmO2aX;uJGF{e2G7	M3jUS\|AvODFvMUCg{txO			MlnNbY5kemWjc3XzJEBkSU2SIHHjZ5VufWyjdHnvci=>	NGnRclQzPTJyM{GxNy=>
ventricular cardiomyocytes	NUO4V5psTnWwY4Tpc44hSXO\|YYm=	MVWwMlAyNTFyIN88US=>			MVfleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=>	NWnmVmNxOjV{MEOxNVM>
BeWo	M4rKOGZ2dmO2aX;uJGF{e2G7	NXTIS3R6OjBiwsXN	NXThdZFMPDhiaB?=	MXXEUXNQyqB?	M3j3UIlv\HWlZYOgZ4VtdCCodYPpc44>	MXiyOVE5PDR5Nx?=
THP-1	MUHGeY5kfGmxbjDBd5NigQ>?	MWSxM\|ExKM7:TR?=	NHvRfWIzyqCq	MnLpSG1UV8Li	M1v3dZN2eHC{ZYPz[ZMhVUOSLUGgdJJw\HWldHnvcuKh	M2n3ZlI2OTV2OEiy
Huh-7	NW\COmtCTnWwY4Tpc44hSXO\|YYm=	NFftc\|ExNTJyIN88US=>	MkXaNkBpyqB?		MULy[ZN2dHS\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4h[y2PeXOg[ZhxemW\|c3nvckBifCC2aHWgdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHN?	MXeyOVExQTh\|NB?=
C6	NIHQV5NHfW6ldHnvckBCe3OjeR?=	MYOxNEDPxE4EoB?=	NHryRpMzOCCvaX6=		NYjHc3gycW6lcnXhd4V{KGODTWCgZYNkfW23bHH0bY9v	MWiyOVA3QTRzNx?=
SW480	MoPOSpVv[3Srb36gRZN{[Xl?	MkPDOFDDqM7:TR?=	M3P6SVQ5yqCq	NG\QeWJFVVOR	NHfwb2li[3SrdnH0[ZMhWFB{QR?=	NE[zPZAzPDl7N{S1NS=>
HT-29	NYrZZpJITnWwY4Tpc44hSXO\|YYm=	NWTOdZVCPDEEoN88US=>	M{XXOFQ5yqCq	NYjlRZVsTE2VTx?=	MnTmZYN1cX[jdHXzJHBROkF?	MoGzNlQ6QTd2NUG=
SW480	M2jkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnibZY1OMLizszN	NYr1eoZTOC15MjDo	NImy[ZdFVVOR	MVHpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	NHPI[o0zPDl7N{S1NS=>
HT-29	M3ixVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\qfWdqPDEEoN88US=>	MmHvNE04OiCq	MnW4SG1UVw>?	Mn7lbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NWjZbVJXOjR7OUe0OVE>
SW480	MULGeY5kfGmxbjDBd5NigQ>?	MnjDOFDDqM7:TR?=	MonkO{Bl	M{\2S2ROW09?	NITDVZBz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg	MYKyOFk6PzR3MR?=
HT-29	M3nlV2Z2dmO2aX;uJGF{e2G7	MXm0NOKh\|ryP	MV63JIQ>	MlvaSG1UVw>?	M4rSWpJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC=	NGfWTnEzPDl7N{S1NS=>
SW480	MXXBdI9xfG:\|aYOgRZN{[Xl?	MUK0NOKh\|ryP	M321cVQ5yqCq	NXLZbYlWTE2VTx?=	M1jaSolv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=>	M2n6fVI1QTl5NEWx
HT-29	NXLqcGhFSXCxcITvd4l{KEG\|c3H5	M2jiPFQxyqEQvF2=	NUPFWpRoPDkEoHi=	NF64UoZFVVOR	MWDpcoR2[2W\|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB\|L{e=	M37vV\|I1QTl5NEWx
SW480	MmruRZBweHSxc3nzJGF{e2G7	Mk\5OFDDqM7:TR?=	MmDwOFjDqGh?	MnrrSG1UVw>?	MmLRbY5lfWOnczDjbIFv\2W\|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?=	M4rZdVI1QTl5NEWx
HT-29	NYnKdXpvSXCxcITvd4l{KEG\|c3H5	NIHqTXk1OMLizszN	MYO0POKhcA>?	MXjEUXNQ	MXPpcoR2[2W\|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS\|	NWnpc45IOjR7OUe0OVE>

... Click to View More Cell Line Experimental Data

Protocol

References

Solubility (25°C)

In vitro	DMSO	82 mg/mL (199.75 mM)
	Ethanol	37 mg/mL (90.13 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Forskolin SDF

Molecular Weight	410.5
Formula	C₂₂H₃₄O₇
CAS No.	66575-29-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Coleonol

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00864578	Withdrawn	Primary Open Angle Glaucoma\|Intraocular Pressure	Sooft Italia	April 2009	--
NCT00863811	Withdrawn	Primary Open Angle Glaucoma\|Intraocular Pressure	Sooft Italia	April 2009	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

Forskolin

Cited by 8 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Forskolin SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

cAMP Signaling Pathway Map

Choose Your Country or Region

By Signaling Pathways

By product type

Forskolin

Cited by 8 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Forskolin SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

cAMP Signaling Pathway Map

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)